Blood-Derived Extracellular Vesicles for Ischemic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for peripheral arterial disease (PAD) are inadequate as patients often experience persistent or recurring symptoms even after successful revascularization, highlighting a need for new therapeutic approaches.
Innovation Solution
The use of extracellular vesicles (EVs) isolated from blood components, specifically serum or plasma, which exhibit strong pro-angiogenic activity, for the treatment of ischemic diseases, injuries, and wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell-derived EVs are used for pro-angiogenic therapy, then therapeutic efficacy is improved, but manufacturing complexity and cost increase due to requiring in vitro culturing of huge amounts of stem cells
Solution Approach 1:
The patent extracts EVs directly from blood components (serum, plasma, whole blood) without requiring stem cell culture. This extraction approach eliminates the complex in vitro culturing process while obtaining EVs with pro-angiogenic activity, directly resolving the contradiction between therapeutic efficacy and manufacturing complexity
Solution Approach 2:
The patent uses EVs from blood components as a substitute copy for stem cell-derived EVs. These blood-derived EVs replicate the pro-angiogenic therapeutic effects without requiring the original stem cell source, thereby simplifying manufacturing while maintaining therapeutic efficacy
2Reliability
If stem cell-derived EVs are used for pro-angiogenic therapy, then therapeutic efficacy is improved, but production time and resource consumption increase due to requiring in vitro culturing of huge amounts of stem cells
Solution Approach 1:
The patent utilizes EVs that are already present in blood components obtained from routine blood donations. This preliminary availability of EVs in the blood supply eliminates the time-consuming in vitro culturing step, directly reducing production time while maintaining therapeutic efficacy
Solution Approach 2:
The patent leverages the body's own blood system as a self-service source of EVs. Blood components naturally contain EVs with pro-angiogenic activity, eliminating the need for external stem cell culture facilities and reducing production time and resource consumption
Data Source
AI summary
The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in wound healing. The extracellular vesicles (EVs) suitable for use in the compositions of the invention are either derived from a blood component or are selected by means of a potency test for pro-angiogenesis. Also disclosed is a method of manufacturing a pharmaceutical preparation of extracellular vesicles (EVs) characterized by a strong proangiogenic activity.